Effekte, Bedingungen und Anwendung von Placebos

• Literatur

• 1 Pepper OHP. A note on the placebo. Ann J Pharm 1945; 117: 409-412
• 2 Beecher HK. The powerful placebo. J Am Med Assoc 1955; 159: 1602-1606
• 3 Jones DS, Podolsky SH. The history and fate of the gold standard. Lancet 2015; 385: 1502-1503
• 4 Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-1602
• 5 Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2010; 1: CD003974
• 6 Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978; 312: 654-657
• 7 de la Fuente-Fernandez R, Ruth TJ, Sossi V. et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166
• 8 Lidstone SC, Schulzer M, Dinelle K. et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010; 67: 857-865
• 9 Brunoni AR, Lopes M, Kaptchuk TJ. et al. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PloS One 2009; 4: e4824
• 10 Benedetti F, Lanotte M, Colloca L. et al. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J Physiol 2009; 587: 3869-3883
• 11 Kaptchuk TJ, Kelley JM, Deykin A. et al. Do “placebo responders” exist?. Contemp Clin Trials 2008; 29: 587-595
• 12 Peciña M, Azhar H, Love TM. et al. Personality trait predictors of placebo analgesia and neurobiological correlates. Neuropsychopharmacol 2013; 38: 639-646
• 13 Darragh M, Booth RJ, Consedine NS. Investigating the ‘placebo personality’outside the pain paradigm. J Psychosom Res 2014; 76: 414-421
• 14 Hall KT, Lembo AJ, Kirsch I. et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 2012; 7: e48135
• 15 Finniss DG, Kaptchuk TJ, Miller F. et al. Biological, clinical, and ethical advances of placebo effects. Lancet 2010; 375: 686-695
• 16 Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996; 64: 535-543
• 17 Scott DJ, Stohler CS, Egnatuk CM. et al. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008; 65: 220-231
• 18 Mayberg HS, Silva JA, Brannan SK. et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-737
• 19 Rief W, Nestoriuc Y, von Lilienfeld-Toal A. et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Safety 2009; 32: 1041-1056
• 20 Kessner S, Sprenger C, Wrobel N. et al. Effect of oxytocin on placebo analgesia: a randomized study. J Am Med Assoc 2013; 310: 1733-1735
• 21 Jensen KB, Petrovic P, Kerr CE. et al. Sharing pain and relief: neural correlates of physicians during treatment of patients. Mol Psychiatry 2014; 19: 392-398
• 22 Enck P, Bingel U, Schedlowski M. et al. The placebo response in medicine: minimize, maximize or personalize?. Nat Rev Drug Discov 2013; 12: 191-204
• 23 Moseley JB, O'Malley K, Petersen NJ. et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347: 81-88
• 24 Fournier JC, DeRubeis RJ, Hollon SD. et al. Anti-depressant drug effects and depression severity: a patient-level meta-analysis. J Am Med Assoc 2010; 303: 47-53
• 25 Gaab J, Blease C, Locher C. et al. Go open: A plea for transparency in psychotherapy. Psychology of Consciousness: Theory, Research, and Practice 2015;
• 26 Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?. J Dev Behav Pediatr 2010; 31: 369-375
• 27 Doering BK, Rief W. Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol Sci 2012; 33: 165-172
• 28 Sandler A, Glesne C, Geller G. Children’s and parents’ perspectives on open-label use of placebos in the treatment of ADHD. Child Care Health Dev 2008; 34: 111-120
• 29 Kaptchuk TJ, Friedlander E, Kelley JM. et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5: e15591
• 30 Fässler M, Meissner K, Schneider A. et al. Frequency and circumstances of placebo use in clinical practice – a systematic review of empirical studies. BMC Med 2010; 8: 15
• 31 Howick J, Bishop FL, Heneghan C. et al. Placebo use in the United Kingdom: results from a national survey of primary care practitioners. PLoS One 2013; 8: e58247